A compound of Formula I: wherein: A is C(R 5) or N; R 5 is H, C 1-3 alkyl, CN or halogen; R 2 is 3-7 membered heterocycloalkyl or 3-7 membered cycloalkyl; optionally substituted with one to three substituents independently selected from the group consisting of R 10, OR 10, SR 10, S R 10, S 2 R 10, C R 10, C OR 10, OC R 10, OC O R 10, NH 2, NH R 10, N(R 10) 2, NHC H, NHC R 10, N R 10 C H, N R 10 C R 10, NHS 2 R 10, NR 10 S 2 R 10, NHC OR 10, NR 10 C OR 10, NHC NH 2, NHC NHR 10, NHC N(R 10) 2, NR 10 C NH 2, NR 10 C NHR 10, NR 10 C N(R 10) 2, C NH 2, C NH R 10, C N(R 10) 2, C NHOH, C NHOR 10, C NHS 2 R 10, C NR 10 S 2 R 10, S 2 NH 2, S 2 NHR 10, S 2 N(R 10) 2, S 2 NHC OR 10, S 2 NR 10 C OR 10, C H, C OH, OH, CN, NO 2, F, Cl, Br and I;, wherein one or more ring CH 2 groups can optionally be replaced by a corresponding number of -C groups, one or more ring sulfur or nitrogen atoms may be optionally oxidized to form S-oxides or N-oxides; R 10, at each occurrence, is independently selected from the group consisting of a 3 to 6 membered cycloalkyl or heterocycloalkyl group, C 1-6 alkyl, -O- C 1-6 alkyl, C 1-6 alkyl-O- C 1-6 alkyl, NH 2, C NH 2, C H, C OH, OH, CN, NO 2, F, Cl, Br and I; wherein two R 10 groups together with the atoms to which they are attached may form a 3 to 6 membered cycloalkyl or heterocycloalkyl group; and each aforementioned R 10 alkyl, cycloalkyl and heterocycloalkyl group may be further substituted with one or two substituents independently selected from CN, OH,halogen, C 1-3 alkyl, -O-C 1-3 alkyl, NH 2, NH- C 1-3 alkyl, and NHC -C 1-3 alkyl. R 4 is wherein X and Y together with the atoms to which they are attached, form a 5 to 7 membered heterocycloalkyl ring which, in addition to the bridge nitrogen, may contain one or two heteroatoms selected from N, O, and S, which ring may be saturated or partially saturated; wherein one or two ring CH 2 groups can optionally be replaced by a corresponding number of -C groups, one or more ring sulfur or nitrogen atoms may be optionally oxidized to form S-oxides or N-oxides and wherein the ring may be substituted on a ring carbon by one or two R 10 substituents or on a ring nitrogen by an R 12 substituent. J is N or CR 11; and R 11 is H, C 1-3 alkyl; R 12 is at each occurrence independently selected from the group consisting of a 3 to 6 membered cycloalkyl or heterocycloalkyl group, C 1-6 alkyl, C 1-6 alkyl-O-C 1-6 alkyl, C NH 2, C H; wherein R 12 alkyl, cycloalkyl and heterocycloalkyl group may be further substituted with one or two substituents independently selected from CN, OH, and halogen, C 1-3 alkyl, NH 2, and NH- C 1-3 alkyl, NHC -C 1-3 alkyl, or pharmaceutical acceptable salts thereof. A is C(R 5) or N; R 5 is H, C 1-3 alkyl, CN or halogen; R 2 is 3-7 membered heterocycloalkyl or 3-7 membered cycloalkyl; optionally substituted with one to three substituents independently selected from the group consisting of R 10, OR 10, SR 10, S R 10, S 2 R 10, C R 10, C OR 10, OC R 10, OC O R 10, NH 2, NH R 10, N(R 10) 2, NHC H, NHC R 10, N R 10 C H, N R 10 C R 10, NHS 2 R 10, NR 10 S 2 R 10, NHC OR 10, NR 10 C OR 10, NHC NH 2, NHC NHR 10, NHC N(R 10) 2, NR 10 C NH 2, NR 10 C NHR 10, NR 10 C N(R 10) 2, C NH 2, C NH R 10, C N(R 10) 2, C NHOH, C NHOR 10, C NHS 2 R 10, C NR 10 S 2 R 10, S 2 NH 2, S 2 NHR 10, S 2 N(R 10) 2, S 2 NHC OR 10, S 2 NR 10 C OR 10, C H, C OH, OH, CN, NO 2, F, Cl, Br and I;, wherein one or more ring CH 2 groups can optionally be replaced by a corresponding number of -C groups, one or more ring sulfur or nitrogen atoms may be optionally oxidized to form S-oxides or N-oxides; R 10, at each occurrence, is independently selected from the group consisting of a 3 to 6 membered cycloalkyl or heterocycloalkyl group, C 1-6 alkyl, -O- C 1-6 alkyl, C 1-6 alkyl-O- C 1-6 alkyl, NH 2, C NH 2, C H, C OH, OH, CN, NO 2, F, Cl, Br and I; wherein two R 10 groups together with the atoms to which they are attached may form a 3 to 6 membered cycloalkyl or heterocycloalkyl group; and each aforementioned R 10 alkyl, cycloalkyl and heterocycloalkyl group may be further substituted with one or two substituents independently selected from CN, OH,halogen, C 1-3 alkyl, -O-C 1-3 alkyl, NH 2, NH- C 1-3 alkyl, and NHC -C 1-3 alkyl. R 4 is wherein X and Y together with the atoms to which they are attached, form a 5 to 7 membered heterocycloalkyl ring which, in addition to the bridge nitrogen, may contain one or two heteroatoms selected from N, O, and S, which ring may be saturated or partially saturated; wherein one or two ring CH 2 groups can optionally be replaced by a corresponding number of -C groups, one or more ring sulfur or nitrogen atoms may be optionally oxidized to form S-oxides or N-oxides and wherein the ring may be substituted on a ring carbon by one or two R 10 substituents or on a ring nitrogen by an R 12 substituent. J is N or CR 11; and R 11 is H, C 1-3 alkyl; R 12 is at each occurrence independently selected from the group consisting of a 3 to 6 membered cycloalkyl or heterocycloalkyl group, C 1-6 alkyl, C 1-6 alkyl-O-C 1-6 alkyl, C NH 2, C H; wherein R 12 alkyl, cycloalkyl and heterocycloalkyl group may be further substituted with one or two substituents independently selected from CN, OH, and halogen, C 1-3 alkyl, NH 2, and NH- C 1-3 alkyl, NHC -C 1-3 alkyl, or pharmaceutical acceptable salts thereof.